Research statistics

Bivalirudin research: publications and trials

What has been published on Bivalirudin: PubMed publications, the kind of evidence they report and registered clinical trials. These are counts of research, not a judgment of whether Bivalirudin works or is safe. For what it is and what the studies found, see the Bivalirudin profile.
Automated weekly refresh · data through November 15, 2026

At a glance

Publications, all years

1,710

Since 1991

Publications in 2026 so far

49

Through November 15, 2026

Human clinical research

51.8%

878 of 1,694 classified

Registered clinical trials

69

ClinicalTrials.gov

Randomized controlled trials

260

Publications reporting an RCT in people

Systematic reviews and meta-analyses

109

Preclinical studies

10.1%

74 animal · 85 in vitro · 12 computational

Records that only mention it

530

Not counted above

Status in the library: FDA-approved. 16 publications are not yet classified by study type.

What to keep in mind

  • Some completed trials have neither posted results nor a linked results publication.

Publications by year

Bivalirudin publications by year and evidence

1991, Preclinical (animal, in vitro, computational): 3 of 31992, Preclinical (animal, in vitro, computational): 5 of 71992, Reviews and meta-analyses: 1 of 71992, Other and not yet classified: 1 of 71993, Human clinical research: 5 of 101993, Preclinical (animal, in vitro, computational): 3 of 101993, Reviews and meta-analyses: 1 of 101993, Other and not yet classified: 1 of 101994, Human clinical research: 3 of 101994, Preclinical (animal, in vitro, computational): 4 of 101994, Reviews and meta-analyses: 1 of 101994, Other and not yet classified: 2 of 101995, Human clinical research: 5 of 161995, Preclinical (animal, in vitro, computational): 3 of 161995, Reviews and meta-analyses: 6 of 161995, Other and not yet classified: 2 of 161996, Preclinical (animal, in vitro, computational): 8 of 141996, Reviews and meta-analyses: 6 of 141997, Human clinical research: 2 of 121997, Preclinical (animal, in vitro, computational): 6 of 121997, Reviews and meta-analyses: 3 of 121997, Other and not yet classified: 1 of 121998, Human clinical research: 5 of 131998, Preclinical (animal, in vitro, computational): 6 of 131998, Reviews and meta-analyses: 2 of 131999, Human clinical research: 3 of 151999, Preclinical (animal, in vitro, computational): 2 of 151999, Reviews and meta-analyses: 9 of 151999, Other and not yet classified: 1 of 152000, Human clinical research: 1 of 132000, Preclinical (animal, in vitro, computational): 1 of 132000, Reviews and meta-analyses: 11 of 132001, Human clinical research: 2 of 132001, Preclinical (animal, in vitro, computational): 1 of 132001, Reviews and meta-analyses: 4 of 132001, Other and not yet classified: 6 of 132002, Human clinical research: 8 of 332002, Preclinical (animal, in vitro, computational): 3 of 332002, Reviews and meta-analyses: 15 of 332002, Other and not yet classified: 7 of 332003, Human clinical research: 13 of 382003, Preclinical (animal, in vitro, computational): 7 of 382003, Reviews and meta-analyses: 15 of 382003, Other and not yet classified: 3 of 382004, Human clinical research: 28 of 542004, Preclinical (animal, in vitro, computational): 4 of 542004, Reviews and meta-analyses: 16 of 542004, Other and not yet classified: 6 of 542005, Human clinical research: 28 of 552005, Preclinical (animal, in vitro, computational): 3 of 552005, Reviews and meta-analyses: 19 of 552005, Other and not yet classified: 5 of 552006, Human clinical research: 34 of 592006, Preclinical (animal, in vitro, computational): 3 of 592006, Reviews and meta-analyses: 16 of 592006, Other and not yet classified: 6 of 592007, Human clinical research: 34 of 692007, Preclinical (animal, in vitro, computational): 8 of 692007, Reviews and meta-analyses: 19 of 692007, Other and not yet classified: 8 of 692008, Human clinical research: 40 of 672008, Preclinical (animal, in vitro, computational): 2 of 672008, Reviews and meta-analyses: 18 of 672008, Other and not yet classified: 7 of 672009, Human clinical research: 41 of 662009, Preclinical (animal, in vitro, computational): 6 of 662009, Reviews and meta-analyses: 12 of 662009, Other and not yet classified: 7 of 662010, Human clinical research: 42 of 782010, Preclinical (animal, in vitro, computational): 3 of 782010, Reviews and meta-analyses: 18 of 782010, Other and not yet classified: 15 of 782011, Human clinical research: 48 of 802011, Preclinical (animal, in vitro, computational): 5 of 802011, Reviews and meta-analyses: 17 of 802011, Other and not yet classified: 10 of 802012, Human clinical research: 38 of 712012, Preclinical (animal, in vitro, computational): 8 of 712012, Reviews and meta-analyses: 14 of 712012, Other and not yet classified: 11 of 712013, Human clinical research: 47 of 802013, Preclinical (animal, in vitro, computational): 6 of 802013, Reviews and meta-analyses: 15 of 802013, Other and not yet classified: 12 of 802014, Human clinical research: 50 of 892014, Preclinical (animal, in vitro, computational): 10 of 892014, Reviews and meta-analyses: 12 of 892014, Other and not yet classified: 17 of 892015, Human clinical research: 45 of 1002015, Preclinical (animal, in vitro, computational): 5 of 1002015, Reviews and meta-analyses: 32 of 1002015, Other and not yet classified: 18 of 1002016, Human clinical research: 38 of 842016, Preclinical (animal, in vitro, computational): 5 of 842016, Reviews and meta-analyses: 26 of 842016, Other and not yet classified: 15 of 842017, Human clinical research: 46 of 802017, Preclinical (animal, in vitro, computational): 6 of 802017, Reviews and meta-analyses: 14 of 802017, Other and not yet classified: 14 of 802018, Human clinical research: 31 of 582018, Preclinical (animal, in vitro, computational): 3 of 582018, Reviews and meta-analyses: 12 of 582018, Other and not yet classified: 12 of 582019, Human clinical research: 31 of 562019, Preclinical (animal, in vitro, computational): 2 of 562019, Reviews and meta-analyses: 9 of 562019, Other and not yet classified: 14 of 562020, Human clinical research: 39 of 622020, Preclinical (animal, in vitro, computational): 8 of 622020, Reviews and meta-analyses: 7 of 622020, Other and not yet classified: 8 of 622021, Human clinical research: 36 of 592021, Preclinical (animal, in vitro, computational): 8 of 592021, Reviews and meta-analyses: 7 of 592021, Other and not yet classified: 8 of 592022, Human clinical research: 30 of 502022, Preclinical (animal, in vitro, computational): 5 of 502022, Reviews and meta-analyses: 10 of 502022, Other and not yet classified: 5 of 502023, Human clinical research: 28 of 562023, Preclinical (animal, in vitro, computational): 4 of 562023, Reviews and meta-analyses: 14 of 562023, Other and not yet classified: 10 of 562024, Human clinical research: 25 of 452024, Preclinical (animal, in vitro, computational): 2 of 452024, Reviews and meta-analyses: 9 of 452024, Other and not yet classified: 9 of 452025, Human clinical research: 29 of 462025, Preclinical (animal, in vitro, computational): 6 of 462025, Reviews and meta-analyses: 6 of 462025, Other and not yet classified: 5 of 462026 (to date), Human clinical research: 23 of 492026 (to date), Preclinical (animal, in vitro, computational): 7 of 492026 (to date), Reviews and meta-analyses: 12 of 492026 (to date), Other and not yet classified: 7 of 49Human clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classified05010019911999200720152026*
Counted PubMed publications by year of first publication. * 2026 runs to November 15, 2026. A larger bar is more publications, not stronger evidence.
Show the data
YearHuman clinical researchPreclinical (animal, in vitro, computational)Reviews and meta-analysesOther and not yet classifiedTotal
199103003
199205117
1993531110
1994341210
1995536216
1996086014
1997263112
1998562013
1999329115
20001111013
2001214613
20028315733
200313715338
200428416654
200528319555
200634316659
200734819869
200840218767
200941612766
2010423181578
2011485171080
2012388141171
2013476151280
20145010121789
20154553218100
2016385261584
2017466141480
2018313121258
201931291456
20203987862
20213687859
202230510550
2023284141056
20242529945
20252966546
2026 (to date)23712749

Study types

Observational human study368
Review299
Randomized controlled trial260
Editorial, letter or other234
Case report187
Meta-analysis95
In vitro study85
Animal study74
Other clinical trial63
Not yet classified16
Systematic review14
Computational study12
Guideline or consensus3

Research areas

From MeSH major topics. A paper can be in several areas.

Cardiovascular1,454
Immune system85
Tissue repair80
Metabolic health62
Neurological and mental health42
Reproductive and sexual health32
Endocrinology22
Antimicrobial and infectious disease18
Gastrointestinal7
Oncology7
Dermatology4
Longevity and aging2

Registered clinical trials

9 of 28 trials completed at least a year before the cutoff have neither posted results nor a linked results publication. A registration is not a result.

Completed: 32 · Unknown status: 21 · Terminated: 6 · Recruiting: 5 · Withdrawn: 3 · Active, not recruiting: 1 · Not yet recruiting: 1
Phase not applicable: 11 · Phase 1: 2 · Phase 2: 5 · Phase 3: 22 · Phase 4: 29

TrialStatusPhaseStartedResults
Bivalirudin with Prolonged Infusion During PCI Versus Heparin After Fibrinolytic TherapyNCT06861374 · 2,400 enrolledNot yet recruitingPhase not applicable2025-05—
Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp SystemNCT06080074 · 50 enrolledRecruitingPhase 22025-04—
Use of Bivalirudin for Anticoagulation in Patients With Extracorporeal Membrane OxygenationNCT06275555 · 154 enrolledRecruitingPhase not applicable2024-06—
BivaLirudin versUS Heparin in Extracorporeal Membrane OxygenationNCT05959252 · 80 enrolledRecruitingPhase 22024-05—
A Study on the Impact of Bivalirudin Usage During PCI for High-risk Plaques on Post-PCI Coronary Microcirculation.NCT05984537 · 70 enrolledRecruitingPhase 42023-07—
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 PatientsNCT05334654 · 58 enrolledCompletedPhase not applicable2022-04—
Bivalirudin vs Heparin in ECMO PatientsNCT03707418WithdrawnPhase 12021-04—
Safety and Efficacy of Bivalirudin During Short-term Intervention of Non-infarction Related Artery After PPCI of STEMINCT04475835 · 100 enrolledUnknown statusPhase not applicable2021-01—
Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial AneurysmsNCT04532333 · 236 enrolledUnknown statusPhase 32020-08—
Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO TrialNCT04445935 · 100 enrolledUnknown statusPhase 42020-06—
Multi-center Application of Bivalirudin in Left Atrial Appendage OcclusionNCT04195997 · 100 enrolledUnknown statusPhase 42020-02—
Bivalirudin in Late PCI for Oatients With STEMINCT04185077 · 1,200 enrolledUnknown statusPhase 42019-11—
Reduce Bolus Injection of BivalirudinNCT03588611 · 204 enrolledCompletedPhase 42019-10—
Safety and Efficacy of Prolonged Use of Bivalirudin 4 Hours After ePCI (COBER Study)NCT04120961 · 330 enrolledCompletedPhase not applicable2019-09—
Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.NCT04046029 · 240 enrolledUnknown statusPhase 42019-07—
Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane OxygenationNCT03965208 · 34 enrolledUnknown statusPhase 42019-05—
Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCINCT03822975 · 6,016 enrolledCompletedPhase not applicable2019-02—
Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial InfarctionNCT03882775 · 240 enrolledUnknown statusPhase 42019-01—
Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCINCT03664180 · 2,989 enrolledCompletedPhase 42019-01—
Clinical Study of Bivalirudin for Percutaneous Coronary Intervention (PCI)NCT03567408 · 200 enrolledUnknown statusPhase 22018-09—
Pharmacokinetics of Bivalirudin for Pediatric AnticoagulationNCT03532399 · 30 enrolledRecruitingPhase not applicable2018-07—
A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular DysfunctionNCT03537586 · 206 enrolledActive, not recruitingPhase not applicable2018-06—
Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMONCT03318393 · 30 enrolledCompletedPhase 42018-03Posted
Bivalirudin in Acute Myocardial InfarctionNCT02897037 · 380 enrolledUnknown statusPhase 32016-11—
Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCINCT02787317 · 1,770 enrolledUnknown statusPhase 42016-05—
Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary AngioplastyNCT02592694 · 1,000 enrolledUnknown statusPhase 42015-10—
Cocktail Injection Improves Outcomes of FFR Guided PCINCT02592720 · 500 enrolledUnknown statusPhase 42015-10—
Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization TrialNCT02448550 · 250 enrolledTerminatedPhase 32015-05—
Bivalirudin Infusion for Ventricular Infarction LimitationNCT02565147 · 78 enrolledTerminatedPhase 32014-12Posted
Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEARTNCT02311231 · 6,012 enrolledCompletedPhase 42014-06—
ENDOvascular Interventions With AngioMAX: The ENDOMAX TrialNCT01913483 · 732 enrolledTerminatedPhase 32013-09Posted
A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCINCT01848106 · 3,232 enrolledTerminatedPhase 32013-09—
Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary AngiographyNCT01848899 · 100 enrolledCompletedPhase 42013-02Posted
Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFHNCT01651780 · 803 enrolledCompletedPhase 32012-10Posted
BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.NCT01696110 · 2,194 enrolledCompletedPhase 42012-08—
Antithrombotic Effects of Ticagrelor Versus ClopidogrelNCT01642238 · 15 enrolledCompletedPhase 42012-07Posted
Bivalirudin Plus Stenting in Long Lesion to Avoid Periprocedural Myocardial Necrosis TrialNCT01555658 · 204 enrolledUnknown statusPhase 32012-04—
How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary InterventionNCT01519518 · 1,829 enrolledCompletedPhase 42012-02Posted
Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioXNCT01433627 · 7,200 enrolledUnknown statusPhase 32011-10—
Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMINCT01158846 · 800 enrolledUnknown statusPhase 42010-08—
FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.NCT01160900 · 180 enrolledUnknown statusPhase 32010-07—
A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary RevascularizationNCT01157455 · 1,900 enrolledUnknown statusPhase 42010-05—
EArly Discharge After Transradial Stenting of CoronarY Arteries in High-Risk Patients of BleedingNCT01084993 · 2,000 enrolledUnknown statusPhase 42010-03—
European Ambulance Acute Coronary Syndrome (ACS) Angiography TrialNCT01087723 · 2,198 enrolledCompletedPhase 32010-03Posted
Efficacy Study of Combined Prasugrel and Bivalirudin Versus Clopidogrel and Heparin in Myocardial InfarctionNCT00976092 · 548 enrolledUnknown statusPhase 42009-09—
Angiomax® or Unfractionated Heparin for Patients Undergoing Percutaneous Coronary InterventionNCT01464671 · 260 enrolledTerminatedPhase 42009-07—
Simplified Anti-Thrombotic Therapy for FFRNCT02384070 · 300 enrolledCompletedPhase not applicable2009-01Posted
Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) PatientsNCT00759083WithdrawnPhase 42008-09—
The UNBLOCK Study: Utilization of Bivalirudin On Clots in KidsNCT00812370 · 18 enrolledCompletedPhase 12008-09—
Anticoagulant Treatments and Percutaneous Coronary AngioplastyNCT00669149 · 99 enrolledTerminatedPhase 42008-06—

The 50 most recently started of 69 trials.

Human trials and evidence reviews

Meta-analyses, systematic reviews and trials in people, newest first.

  1. Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.

    Annals of cardiac anaesthesia · October 12, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42862663 · DOI 10.4103/aca.aca_28_26 · Reviews and meta-analyses

  2. Comparison of bivalirudin versus heparin in percutaneous coronary intervention for patients with acute coronary syndrome: A meta-analysis.

    Medicine · September 1, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42798052 · DOI 10.1097/md.0000000000050046 · Reviews and meta-analyses

  3. Effectiveness and safety of bivalirudin anticoagulation therapy in adult patients receiving extracorporeal membrane oxygenation: A systematic review and meta-analysis.

    Medicine · August 1, 2025 · Meta-analysis · cited 3 times · open access

    PMID 40826747 · DOI 10.1097/md.0000000000042696 · Reviews and meta-analyses

  4. Dosing Reliability of Direct Thrombin Inhibitors in Extracorporeal Membrane Oxygenation: A Systematic Review and Meta-Analysis.

    ASAIO journal (American Society for Artificial Internal Organs : 1992) · July 17, 2025 · Meta-analysis · cited 15 times

    PMID 40673548 · DOI 10.1097/mat.0000000000002512 · Reviews and meta-analyses

  5. Bivalirudin Versus Heparin in Patients Undergoing Percutaneous Coronary Intervention in Acute Coronary Syndromes.

    Critical pathways in cardiology · February 21, 2025 · Meta-analysis · cited 2 times

    PMID 39133562 · DOI 10.1097/hpc.0000000000000372 · Reviews and meta-analyses

  6. The efficacy and safety of bivalirudin and heparin in patients with acute coronary syndrome: a systematic review and meta-analysis.

    Systematic reviews · February 10, 2025 · Meta-analysis · cited 3 times · open access

    PMID 39930484 · DOI 10.1186/s13643-025-02782-7 · Reviews and meta-analyses

  7. Revisiting the Efficacy and Safety of Bivalirudin in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: Insights From a Mixed Treatment Comparison Meta-Analysis of Randomized Trials.

    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · November 6, 2024 · Meta-analysis · cited 0 times

    PMID 39506500 · DOI 10.1002/ccd.31276 · Reviews and meta-analyses

  8. Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 Results.

    Journal of the American College of Cardiology · October 1, 2024 · Meta-analysis · cited 24 times · open access

    PMID 39384262 · DOI 10.1016/j.jacc.2024.07.045 · Reviews and meta-analyses

  9. Bivalirudin Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Study-level Meta-analysis of Randomized Controlled Trials.

    Cardiovascular drugs and therapy · July 30, 2024 · Meta-analysis · cited 3 times

    PMID 39080125 · DOI 10.1007/s10557-024-07609-6 · Reviews and meta-analyses

  10. Differential Use of Glycoprotein IIb/IIIa Inhibitors with Bivalirudin in Patients with STEMI Undergoing PCI: A Systematic Review and Meta-Analysis.

    American journal of cardiovascular drugs : drugs, devices, and other interventions · April 29, 2024 · Meta-analysis · cited 1 times

    PMID 38683263 · DOI 10.1007/s40256-024-00636-6 · Reviews and meta-analyses

Most cited

By OpenAlex citation count. Citations measure attention, not quality or correctness.

  1. Bivalirudin during primary PCI in acute myocardial infarction.

    The New England journal of medicine · May 1, 2008 · Randomized controlled trial · cited 1,867 times · open access

    PMID 18499566 · DOI 10.1056/nejmoa0708191 · Human clinical research

  2. Bivalirudin for patients with acute coronary syndromes.

    The New England journal of medicine · November 1, 2006 · Randomized controlled trial · cited 1,472 times · open access

    PMID 17124018 · DOI 10.1056/nejmoa062437 · Human clinical research

  3. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.

    JAMA · February 1, 2003 · Randomized controlled trial · cited 1,162 times

    PMID 12588269 · DOI 10.1001/jama.289.7.853 · Human clinical research

  4. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

    Chest · February 1, 2012 · Review · cited 1,094 times · open access

    PMID 22315264 · DOI 10.1378/chest.11-2291 · Reviews and meta-analyses

  5. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial.

    Journal of the American College of Cardiology · March 9, 2007 · Randomized controlled trial · cited 799 times · open access

    PMID 17394970 · DOI 10.1016/j.jacc.2007.02.027 · Human clinical research

Latest publications

  1. Bivalirudin With a High-Dose Post-PCI Infusion Versus Heparin During Primary PCI in STEMI: One-Year Results From the BRIGHT-4 Trial.

    Circulation. Cardiovascular interventions · October 31, 2026 · Randomized controlled trial · cited 0 times

    PMID 42965935 · DOI 10.1161/circinterventions.126.017029 · Human clinical research

  2. Comprehensive analysis of peptide pharmaceutical: Development of three orthogonal chromatographic methods and characterization of bivalirudin degradation products by high-resolution mass spectrometry.

    Journal of pharmaceutical and biomedical analysis · October 12, 2026 · In vitro study · cited 0 times

    PMID 42879990 · DOI 10.1016/j.jpba.2026.117761 · In vitro studies

  3. Bivalirudin Versus Heparin and Protamine in Adult Patients Undergoing Cardiac Surgery: A Systematic Review and Meta-Analysis.

    Annals of cardiac anaesthesia · October 12, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42862663 · DOI 10.4103/aca.aca_28_26 · Reviews and meta-analyses

  4. Engineering Immunomodulatory Stents Using a Biomimetic Nanozyme System for Vascular Healing.

    Advanced materials (Deerfield Beach, Fla.) · October 5, 2026 · Animal study · cited 0 times · open access

    PMID 42830705 · DOI 10.1002/adma.75212 · Animal studies

  5. Known Unknowns: Unpacking Controversies and Uncertainties in the 2025 Guidelines for Management of Acute Coronary Syndromes.

    Current cardiology reports · October 5, 2026 · Review · cited 0 times

    PMID 42832065 · DOI 10.1007/s11886-026-02427-8 · Reviews and meta-analyses

  6. Clinical outcomes of bivalirudin and heparin in pediatric extracorporeal membrane oxygenation: A systematic review and meta-analysis.

    The International journal of artificial organs · September 16, 2026 · Review · cited 0 times · open access

    PMID 42746993 · DOI 10.1177/03913988261481295 · Reviews and meta-analyses

  7. Real-world outcomes of unfractionated heparin plus antithrombin concentrate versus bivalirudin in adult patients undergoing extracorporeal membrane oxygenation.

    The journal of extra-corporeal technology · September 15, 2026 · Observational human study · cited 0 times · open access

    PMID 42743424 · DOI 10.1051/ject/2026015 · Human clinical research

  8. Comparison of bivalirudin versus heparin in percutaneous coronary intervention for patients with acute coronary syndrome: A meta-analysis.

    Medicine · September 1, 2026 · Meta-analysis · cited 0 times · open access

    PMID 42798052 · DOI 10.1097/md.0000000000050046 · Reviews and meta-analyses

  9. Bivalirudin in Primary PCI: Time to Implement the Overwhelming Evidence?

    Journal of the American College of Cardiology · August 28, 2026 · Editorial, letter or other · cited 0 times · open access

    PMID 42663361 · DOI 10.1016/j.jacc.2026.07.012 · Commentary and other

  10. Bivalirudin Versus Heparin in Low and Non-Low Bleeding Risk Patients Undergoing Primary PCI for STEMI: The BRIGHT-4 Trial.

    Journal of the American College of Cardiology · August 28, 2026 · Randomized controlled trial · cited 1 times

    PMID 42663356 · DOI 10.1016/j.jacc.2026.06.035 · Human clinical research

Browse all 1,710 publications in the dashboard

How this is counted

PubMed records matched by the names below, counted when the peptide is in the title, indexed by MeSH, or confirmed from the abstract. The exact query can be rerun on Europe PMC. Methodology

Search terms: Angiomax; Bivalirudin; Hirulog

((TITLE_ABS:"Angiomax" OR CHEM:"Angiomax") OR (TITLE_ABS:"Bivalirudin" OR CHEM:"Bivalirudin") OR (TITLE_ABS:"Hirulog" OR CHEM:"Hirulog")) AND SRC:MED

Cite this page

Peptide Library. (2026, November 16). Bivalirudin research statistics (Version weekly-2026-11-15) [Statistic]. Peptide Library. https://peptidelibrary.app/research/peptides/bivalirudin